Caricamento...
Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir was developed to deliver enhanced antiviral potency and reduced systemic toxicities by more efficient intracellular delivery of the active metabolite tenofovir disphosphate than tenofovir disoproxil fumarate (TDF). In two randomized, double-b...
Salvato in:
| Pubblicato in: | Therap Adv Gastroenterol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6048601/ https://ncbi.nlm.nih.gov/pubmed/30034532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818786108 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|